


## Pimodivir HCl

### Chemical Properties

CAS No. : 1777721-70-6  
 Formula: C<sub>20</sub>H<sub>19</sub>F<sub>2</sub>N<sub>5</sub>O<sub>2</sub>ClH·1/2H<sub>2</sub>O  
 Molecular Weight: 444.86  
 Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year  
 Actual storage temperature shall be subject to the COA.



### Biological Description

Description	Pimodivir is an inhibitor of influenza virus replication that blocks the PB2 cap-snatching activity of the influenza viral polymerase complex. The cell-based EC <sub>50</sub> for VX-787 is 1.6 nM in a cytopathic effect (CPE) assay. VX-787 is active against a diverse panel of influenza A virus strains.
Targets(IC <sub>50</sub> )	Others, Influenza Virus

### Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.2479 mL	11.2395 mL	22.479 mL
5 mM	0.4496 mL	2.2479 mL	4.4958 mL
10 mM	0.2248 mL	1.1239 mL	2.2479 mL
50 mM	0.045 mL	0.2248 mL	0.4496 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Boyd MJ, Bandarage UK, Bennett H, Byrn RR, Davies I, Gu W, Jacobs M, Ledebner MW, Ledford B, Leeman JR, Perola E, Wang T, Bennani Y, Clark MP, Charifson PS. Isosteric replacements of the carboxylic acid of drug candidate VX-787: Effect of charge on antiviral potency and kinase activity of azaindole-based influenza PB2 inhibitors. *Bioorg Med Chem Lett*. 2015 May 1;25(9):1990-4. doi: 10.1016/j.bmcl.2015.03.013. Erratum in: *Bioorg Med Chem Lett*. 2016 Jan 1;26(1):240. PubMed PMID: 25827523.

Byrn RA, Jones SM, Bennett HB, Bral C, Clark MP, Jacobs MD, Kwong AD, Ledebner MW, Leeman JR, McNeil CF, Murcko MA, Nezami A, Perola E, Rijnbrand R, Saxena K, Tsai AW, Zhou Y, Charifson PS. Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit. *Antimicrob Agents Chemother*. 2015 Mar;59(3):1569-82. doi: 10.1128/AAC.04623-14. PubMed PMID: 25547360; PubMed Central PMCID: PMC4325764.

Clark MP, Ledebner MW, Davies I, et al. Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2. *J Med Chem*. 2014 Aug 14;57(15):6668-78. doi: 10.1021/jm5007275. PubMed PMID: 25019388.

Smee DF, Barnard DL, Jones SM. Activities of JNJ63623872 and oseltamivir against influenza A H1N1pdm and H3N2 virus infections in mice. *Antiviral Res*. 2016 Dec;136:45-50. doi: 10.1016/j.antiviral.2016.10.009. PubMed PMID: 27771390.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481